Lower serum magnesium concentration and higher 24-h urinary magnesium excretion despite higher dietary magnesium intake in athletes:a systematic review and meta-analysis

Magnesium plays a critical role in the human's life activities and energy metabolism. This study aimed to evaluate the magnesium status of athletes via a systematic review of cross-sectional studies. A comprehensive systematic search was conducted in PubMed, Web of Science, SPORTDiscus, Cochrane Library electronic databases, and other sources before April 5, 2021. Fourteen studies were included in the systematic review, involving 855 athletes and 521 control subjects. Serum magnesium concentration was significantly lower in athletes(mean difference(MD):-0.04 mmol/L;95% confidence interval(CI):-0.06 to-0.01;P = 0.02)in spite of significantly higher dietary magnesium intake(MD: 51.72 mg/day;95% CI: 14.62 to 88.83;P = 0.006). Meta-analysis showed that 24-h urinary magnesium excretion in athletes was significantly higher than that in the untrained population(MD: 0.76 mmol/day;95% CI: 0.11 to 1.41;P = 0.02). Despite higher total dietary magnesium intake, athletes generally have lower serum magnesium concentration and higher 24-h urinary magnesium excretion, demonstrating that the magnesium requirement of athletes is higher than the untrained population. It is necessary to carry out a dietary assessment and nutrition counseling to help athletes adopt proper diets to meet their nutritional needs in exercise.

Serum Magnesium Levels in Second and Third Trimesters of Pregnancy in Patients That Developed Pre-Eclampsia and Feto-Maternal Outcome

Introduction: Pregnancy is a physiological process that may be complicated by a number of clinical conditions. Gestational diabetes and pre-eclampsia are known complications in pregnancy. Pre-eclampsia is a disease of hypothesis in which the pathogenesis is yet to be fully explained. The role of magnesium in the pathogenesis of pre-eclampsia has been suggested by studies and it is being investigated all over the world. The study aimed to compare serum magnesium levels in pre-eclampsia and control groups from second trimester of pregnancy and assessed maternofetal outcome. Materials and Methods: This was a nested case control study in which consenting three hundred and sixty (360) normal pregnant women were enrolled. These women were recruited in their second trimester of pregnancy. Blood samples for serum magnesium estimation were obtained from subjects and controls at recruitment and after development of pre-eclampsia. Results: Thirty seven pregnant women that developed pre-eclampsia were nested as cases and were matched with 37 controls (apparently healthy pregnant women). The mean serum magnesium at recruitment was 0.75 ± 0.028 mmol/l (cases) and 0.76 ± 0.036 mmol/l (controls) (P = 0.123);this became significant when diagnosis of pre-eclampsia were made with mean of 0.53 ± 0.06 mmol/l (cases) and 0.69 ± 0.08 mmol/l (controls), (P 0.001). There was significant statistical relationship between preterm delivery, low birth weight and need for special care baby unit (SCBU) admission in newborn of mothers with low serum magnesium level (P = 0.001, 0.002 and 0.035 respectively). Conclusion: Findings from this study revealed that hypomagnesaemia appears to be a complication of pre-eclampsia. Serum levels of magnesium were normal until the development of the disease. Serum level of this biomarker affects maternofetal outcome significantly.

The Possible Role Serum Biochemical Analysis Can Play in Predicting an Infant’s Risk of Retinopathy of Prematurity;Elevated Serum Magnesium

Purpose: We evaluated biochemical analysis results with the aim of discovering serum levels that have possible effects on the development of retinopathy of prematurity (ROP). Methods: A retrospective study was conducted between January 2017 and January 2018 on a total of 110 infants with 35 or less gestational weeks. The sample included 78 infants who had been diagnosed with different stages of ROP and 32 infants without ROP. Results from routine serum biochemical analyses, performed at birth and at one month after birth, were evaluated. The Independent Sample t-test and Mann-Whitney U test were performed to compare the data. Results: The infants with ROP were born at a mean of 28.0 (±2.1) weeks of gestation, weighing a mean of 1066 (±314) g, and the mean duration of stay in the incubator was 38.2 (±19) days. The infants without ROP were born at a mean of 29.6 (±2.6) weeks of gestation, weighing a mean of 1265 (±372) g. 59 infants (53.6%) were females, and 51 (46.4%) were males. Between infants with and without ROP, differences in the following levels were not statistically significant: glucose, blood urine nitrogen, creatinine, alanine aminotransferase, aspartate aminotransferase, albumin, total protein, direct bilirubin, indirect bilirubin, uric acid, and phosphorus. Serum magnesium (Mg) levels at birth in infants with ROP were significantly higher than infants without ROP (p = 0.014). Conclusions: Serum Mg levels at birth were found to be higher in infants with ROP than in those without ROP. The levels may be dependent on the mothers’ treatment of Mg for different medical reasons.

Serum Magnesium Levels in Healthy Pregnant and Pre-Eclamptic Patients <br/>—A Cross-Section Study

Background: Pre-eclampsia complicates 2% - 8% of pregnancies. Various efforts have been put forward for its prevention and treatment. Magnesium sulphate is presently the recommended drug for the prevention and treatment of eclampsia and severe pre-eclampsia. Objectives: The study aimed to compare the serum magnesium in a healthy pregnant women and pre-eclamptic women. It determined demographic characteristic of the study population and recommended the prophylactic usage of magnesium sulphate in pregnancy in our environment. Method: This was a prospective case control study comparing the serum magnesium levels in pre-eclampsia and normal pregnancy tertiary hospitals. The women who satisfied the inclusion criteria were recruited in the two groups (seventy five in the healthy pregnant women and seventy five in the pre-eclamptic women). The blood samples were collected and analysed for the serum magnesium and urine sample for urinalysis. Result: Total of 150 patients comprises 75 normal pregnant women and 75 cases of pre-eclampsia. The mean serum magnesium in the normal pregnant women was 0.73 (±0.14) mmol/L while in preeclampsia the level was 0.58 (±0.17) mmol/L. This is statistically significant (t = 6.120, p = 0.000). There was significance difference in the mean age of patients with pre-eclampsia and normal pregnancy. The mean parity in the pre-eclampsia was 0.80 and in the normal pregnancy was 1.4 and was statistically significant (t = 3.40, p value < 0.001). The mean gestational age of the pre-eclamptic was 36.5 weeks while it was 28.7 weeks in the normal pregnant women (t = 10.80, p = 0.000). Conclusion: The findings in this research work revealed that the pre-eclamptic women have lower serum magnesium level compared to the normal pregnant women, and it may therefore be interesting to do a larger multicenter study with possibility of developing a marker for this disease of theories.

Determination of Magnesium in whole Blood and Serum of Ischemic Heart Disease(IHD) Patients by Flame Atomic Absorption Spectrometry

Flame atomic absorption spectrometric determination of magnesium in whole blood and serum of ischemic heart disease patients and control with different ages and sex was proposed. The limiting interfering phosphate/magnesium ratio have been estimates.2%w/v AlCl3.6H2O was found to be very influential in removing phosphate interference effects. The detection limit was 0.065 μg/mL .Magnesium added to blood and serum sample, and carried through this method may be recovered completely (96% - 100%) recovery percentage. The suggested method is simple, fast and selective. The statistical analysis of magnesium levels in blood and serum showed that blood and serum magnesium levels in patients were lower than magnesium contents of control group. Magnesium levels in blood and serum of males were significantly lower than females and the magnesium levels were age independent. These findings indicates that there was an association between blood and serum magnesium deficiency which can induce an entire array of path physiological phenomena known to be important in ischemic heart disease.

镁补充改善糖尿病患者血清胰岛素水平的Meta分析

系统评价口服镁补充改善糖尿病患者血清胰岛素水平的效果。采用计算机检索PubMed、EBSCO、The Cochrane Library、CNKI、Web of Science数据库,搜集口服镁补充改善糖尿病患者血清胰岛素水平的相关研究,独立筛查文献、提取资料并评价纳入研究的偏倚风险后采用R studio软件进行Meta分析。亚组分析结果显示,口服镁补充在镁缺乏糖尿病患者中[SMD=-0.29,95%CI(-1.07,0.48),P>0.01]、4~6周补充周期[SMD=-0.74(-1.69,0.20),P>0.01]、250~300 mg/d剂量[SMD=-63(-1.25,0),P<0.01]改善血清胰岛素水平效果更佳,说明口服镁补充对于改善糖尿病患者血清胰岛素水平具有良好的效果。

血清镁离子浓度与直肠癌患者谷氨酰转肽酶的关系

直肠癌患者血清镁离子(Mg^(2+))浓度对γ-谷氨酰转肽酶(γ-GT)的影响尚不明确,收集分析临床数据,Mg^(2+)浓度不呈正态分布(D=0.737,P<0.05),按照中位数分组,比较不同组间临床病理特征的差异,用局部加权散点平滑(LOWESS)、分段线性回归方法,拟合血清Mg^(2+)浓度与γ-GT的关系。结果发现,与Mg^(2+)浓度小于0.92 mmol/L组的直肠癌患者比较,Mg^(2+)浓度≥0.92 mmol/L组的γ-GT和血清总胆固醇较高(P均<0.05)。LOWESS的结果表明,原始数据中血清Mg^(2+)浓度的两个变化点分别为0.92 mmol/L和0.99 mmol/L,自然对数转换的数据中血清Mg^(2+)浓度的另外两个变化点分别为-0.167和-0.01。利用原始数据建立的两段线性回归模型表明,血清Mg^(2+)浓度的变化点为0.98 mmol/L,Mg^(2+)浓度<0.98 mmol/L对γ-GT有正向影响,Mg^(2+)≥0.98 mmol/L时有负向影响。另一个使用自然对数转换数据的两段线性回归模型显示,血清Mg^(2+)浓度的变化点为0.01,其中Mg^(2+)浓度的自然对数<0.01对γ-GT有正向影响,当Mg^(2+)浓度的自然对数≥0.01时则有负向影响。用原始数据LOWESS回归的2个拐点,即0.92 mmol/L和0.99 mmol/L的Mg^(2+)浓度,进行三段线性回归分析,结果显示,<0.980 mmol/L的Mg^(2+)浓度,对γ-GT的影响是正向的,且与<0.929 mmol/L的Mg^(2+)浓度区间的系数不同,影响程度不同,而在≥0.980 mmol/L的Mg^(2+)浓度区间,对γ-GT的影响是负向的,此外,用对数转换数据LOWESS的2个拐点进行的三段线性回归,也显示Mg^(2+)浓度的自然对数以-0.020为分界点时,对γ-GT的影响方向是相反的,但三段线性回归模型均没有统计学意义,总之,具有较高Mg^(2+)浓度的直肠癌患者,其γ-GT的水平也较高,Mg^(2+)浓度对γ-GT的影响存在拐点效应,为γ-GT的关联因素研究提供了基础。

血清镁在急性肾损伤诊疗中的研究进展

急性肾损伤(acute kidney injury,AKI)是威胁健康的急重症,在临床工作中常见。AKI的发生往往延长患者康复时间并降低其长期生活质量。由于缺乏特定的治疗手段,早诊断并对症治疗是提高AKI患者预后的关键。血清镁浓度的变化与AKI的发生及预后存在一定关联,并在AKI的诊断及治疗中发挥重要作用。本文就镁的分布与稳态调节、血清镁与AKI的相关性及镁离子紊乱诱发AKI的可能机制进行介绍,并列举了镁补充剂在AKI防治中的应用实例,旨在加强临床医师对人体镁稳态的认识,及时纠正镁失衡以改善AKI患者的预后。

莫沙必利联合奥美拉唑镁对反流性食管炎患者胃分泌功能、血清Ghrelin、Leptin水平的影响

目的探讨莫沙必利联合奥美拉唑镁对反流性食管炎患者胃分泌功能、血清人生长素释放多肽(Ghrelin)、瘦素(Leptin)水平的影响作用。方法回顾性选取2022年2月~2023年2月泸县人民医院诊治的180例反流性食管炎患者,根据治疗方案分为奥美拉唑镁组(n=86)和联合用药组(n=94)。奥美拉唑镁组使用奥美拉唑镁肠溶片进行治疗,联合用药组在奥美拉唑镁组的基础上联合枸橼酸莫沙必利片进行治疗。比较两组患者的临床疗效;比较两组患者胃分泌功能[胃泌素(GAS)、胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)、胃动素(MOT)、血管活性肠肽(VIP)]变化情况;比较两组患者血清Ghrelin和Leptin水平;比较两组患者治疗期间不良反应情况。结果联合用药组的总有效率(94.68%)显著高于奥美拉唑镁组的总有效率(81.40%),差异有统计学意义(χ^(2)=7.692,P<0.05)。治疗后,两组患者PGⅡ、VIP、Leptin水平显著低于治疗前,且联合用药组PGⅡ、VIP、Leptin水平明显低于奥美拉唑镁组[(14.85±1.73)μg L vs.(21.51±2.11)μg L、(13.41±1.27)pg ml vs.(20.45±1.15)pg ml、(8.11±1.13)pg ml vs.(16.52±2.73)pg ml],差异有统计学意义(t=23.236、38.857、27.416,P<0.05)。治疗后,两组患者GAS、PGⅠ、MOT、Ghrelin水平明显高于治疗前,且联合用药组GAS、PGⅠ、MOT、Ghrelin水平明显高于奥美拉唑镁组[(96.85±5.81)pg ml vs.(78.76±4.87)pg ml、(132.71±11.26)μg L vs.(120.42±10.84)μg L、(280.24±21.67)pg ml vs.(200.56±17.62)pg ml、(26.46±3.41)pg ml vs.(19.64±3.85)pg ml],差异有统计学意义(t=22.527、7.446、26.915、12.602,P<0.05)。治疗期间两组不良反应差异无统计学意义(χ^(2)=1.738,P>0.05)。结论莫沙必利联合奥美拉唑镁治疗反流性食管炎患者临床效果显著,安全性比较好,可以有效改善胃分泌功能,调节血清Ghrelin、Leptin水平平衡,进而改善反流现象,具有良好的临床应用价值。

慢性阻塞性肺疾病患者气道炎症反应、肺功能与生化指标相关性研究

目的:分析慢性阻塞性肺疾病(COPD)患者气道炎症反应、肺功能、血清1,25-二羟基维生素D_(3)[1,25(OH)_(2)D_(3)]、钙离子(Ca^(2+))、镁离子(Mg^(2+))水平变化,并探究气道炎症反应、肺功能与血清1,25(OH)_(2)D_(3)、Ca^(2+)、Mg^(2+)的相关性。方法:选择COPD住院患者48例(急性加重组)和COPD门诊随访患者48例(稳定组),以40例同期无COPD病史的健康者为对照组。检测三组呼出气一氧化氮(FeNO)、C反应蛋白(CRP)、降钙素原(PCT)、第一秒用力呼气末容积(FEV1)、一秒率(FEV1/FVC)、血清1,25(OH)_(2)D_(3)、Ca^(2+)和Mg^(2+),并分析FeNO、CRP、PCT、FEV1、FEV1/FVC水平与1,25(OH)_(2)D_(3)、Ca^(2+)、Mg^(2+)水平的相关性。结果:随着COPD病情进展,患者FEV1、FEV1/FVC、1,25(OH)_(2)D_(3)、Ca^(2+)、Mg^(2+)水平均降低,急性加重组1,25(OH)_(2)D_(3)、Ca^(2+)、Mg^(2+)水平低于稳定组,同时患者FeNO、CRP、PCT水平均升高,急性加重组的FeNO、CRP、PCT水平高于稳定组(均P<0.05)。FeNO、CRP、PCT水平分别与1,25(OH)_(2)D_(3)、Ca^(2+)、Mg^(2+)水平呈负相关(均P<0.05),FEV1、FEV1/FVC水平分别与1,25(OH)_(2)D_(3)、Ca^(2+)、Mg^(2+)水平呈正相关(均P<0.05)。CRP、PCT是COPD急性加重的危险因素(均P<0.05),FEV1、FEV1/FVC、1,25(OH)_(2)D_(3)是COPD急性加重的保护因素(均P<0.05)。结论:气道炎症与1,25(OH)_(2)D_(3)、Ca^(2+)、Mg^(2+)水平呈负相关,肺功能与1,25(OH)_(2)D_(3)、Ca^(2+)、Mg^(2+)水平呈正相关,CRP、PCT是COPD急性加重的危险因素,FEV1、FEV1/FVC、1,25(OH)_(2)D_(3)是COPD急性加重的保护因素,其具体机制还有待深入研究。

Spectrofluorimetric Determination of Magnesium (Ⅱ) with 7-(8-Hydroxy-3, 6-Disulfonaphthylazo)-8-Hydroxyquinoline-5-Sulfonic Acid

A new fluorescent reagent, 7 (8 hydroxy 3, 6 disulfonaphthylazo) 8 hydroxyquinoline 5 sulfonic acid (HDNHQ) for the determination of magnesium has been developed. It reacted with magnesium to form a 1∶1 fluorescent complex with λ ex / λ em =356/495 nm immediately at room temperature in ammonia ammonium chloride buffer (pH 10.7). A linear relationship was obtained in the magnesium concentration range of 0 160 ng·mL -1 with the detection limit of 0.04 ng·mL -1 . The proposed method was simple, rapid and sensitive. It has been successfully applied to the determination of trace magnesium in blood serum with recoveries of 103.75% and 98.16%, respectively.

维持性血液透析患者血镁水平与死亡率关系的研究

目的探究维持性血液透析(maintenance hemodialysis,MHD)患者血镁水平与全因死亡、心脑血管死亡及非心脑血管死亡的相关性。方法纳入2014年1月1日~2020年1月1日在重庆医科大学附属第二医院行MHD的患者。收集透析前基线数据及开始透析后每3个月的临床随访数据进行分析。按平均血镁值四分位数进行分组:Q1组(血镁≤0.98mmol/L)、Q2组(0.98<血镁≤1.06mmol/L)、Q3组(1.06<血镁≤1.13mmol/L)、Q4组(血镁>1.13mmol/L);结合限制性立方样条模型将Q2、Q3组合并为Qi组(0.98<血镁≤1.13mmol/L),Q1、Q4组合并为Qo组。Kaplan-Meier法用于生存分析,COX风险回归模型用于分析死亡率的影响因素。结果共纳入182例MHD患者,其中Q1组46例,Q2组45例,Q3组46例,Q4组45例。Kaplan-Meier生存分析提示:4组间总体的生存率有统计学差异(Log-rankχ^(2)=9.024,P=0.029)。Qi组与Qo组总体及非心脑血管的生存率有统计学差异(Log-rankχ^(2)=8.892,P=0.003;Log-rankχ^(2)=7.385,P=0.007)。COX回归模型结果发现:以Qi组为对照组,Qo组患者的全因死亡风险及非心脑血管死亡风险更高,校正混杂因素后Qo组较Qi组全因死亡风险增加88.7%(HR=1.887,95%CI:1.012~3.519,P=0.046)。结论本研究发现血镁水平与MHD患者全因死亡率相关,当0.98<血镁≤1.13mmol/L时全因死亡率更低。

老年维持性血液透析病人血镁水平及其临床意义

目的调查老年维持性血液透析(maintenance hemodialysis,MHD)病人血镁水平,分析不同血镁水平病人的血压、全段甲状旁腺激素(intact parathyroid hormone,iPTH)水平及营养状况。方法选择99例透析充分的老年MHD病人,根据透析前血镁水平将病人分为低镁组(<0.75 mmol/L,n=24)、正常组(0.75~1.02 mmol/L,n=45)和高镁组(>1.02 mmol/L,n=30),比较3组透析前血钙、血磷、iPTH、血浆白蛋白、Hb的水平以及透析中和透析间期的血压。结果不同血镁水平病人透析间期血压无明显变化,低镁组透析中SBP明显低于正常组和高镁组(P<0.01),DBP明显低于正常组(P<0.01)。3组间血iPTH、血钙、血磷、Hb水平按低镁组、高镁组、正常组依次升高,且3组间差异均有统计学意义(均P<0.01);正常组血浆白蛋白和Hb水平明显高于低镁组(P<0.05)。结论老年MHD病人血镁水平正常或升高者通常营养指标较好,透析中血压相对稳定,同时iPTH水平偏高。

血清镁水平联合血小板与淋巴细胞比值用于辅助诊断肢体创伤后骨髓炎的临床价值

目的:探讨血清镁和血小板与淋巴细胞比值(PLR)在辅助诊断肢体创伤后骨髓炎(PTOM)的作用。方法:选取2013—至2018年我院收治的78例肢体PTOM患者作为PTOM组,以89例无菌性骨不连(ABN)患者作为ABN组,以同期骨折愈合患者100例作为对照组。采用日立AU5832全自动生化分析仪和Sysmex XN-2800全自动血细胞分析仪检测血清镁水平和全血细胞计数,进一步计算PLR和中性粒细胞与淋巴细胞计数比值(NLR)。结果:PTOM组血清镁低于对照组和ABN组,PLR高于对照组和ABN组,而NLR高于对照组(P<0.05)。PTOM组患者血清镁水平和PLR与年龄、性别分层无关(P>0.05)。logistic回归分析结果表明,血清镁和PLR为肢体PTOM的独立影响因素(P<0.05)。PTOM患者血清镁水平与PLR无显著相关性(r=-0.086,P>0.05)。ROC曲线下面积(AUC)表明血清镁水平(AUC=0.816,95%CI:0.753~0.879)和PLR(AUC=0.728,95%CI:0.649~0.808)的AUC可接受准确性较高(AUC>0.7)。二者联合预测AUC值为0.886(95%CI:0.835~0.936),灵敏度和特异性分别为85.9%、78.0%。血清镁水平2.25 mg/dL和PLR181.35被确定为最佳截止值。结论:血清镁降低和PLR升高与PTOM密切相关,血清镁水平联合PLR检测有可能成为辅助诊断肢体PTOM的有效方法。

慢性肾病患者低镁血症与动脉粥样硬化发生的相关性分析

目的探讨慢性肾病(CKD)患者低镁血症与动脉粥样硬化(AS)发生的相关性。方法选择2017年1月至2020年1月期间于新疆军区总医院北京路医疗区肾脏内科住院的CKD 5期患者402例,根据颈动脉超声检查结果,将患者分为AS组140例和非AS组262例,比较两组临床检查指标,血清镁、超敏C反应蛋白(hs-CRP)、颈动脉内中膜厚度(IMT)和肾小球滤过率估算值(eGFR)水平。多因素Logistic回归分析CKD患者并发AS的独立危险因素,分析血清镁与hs-CRP、IMT和eGFR的相关性。采用ROC曲线分析低镁血症对CKD患者发生AS的预测价值。结果AS组有高血压史的患者比例更高,且低密度脂蛋白胆固醇(LDL-C)、hs-CRP、尿酸(UA)水平和IMT均显著高于非AS组,而血清镁和eGFR水平低于非AS组(t/χ^(2)=4.109、3.584、10.877、2.459、26.035、5.652、7.040,P<0.05)。血清镁、hs-CRP、IMT和eGFR均为CKD患者合并AS的影响因素[OR(95%CI)=3.221(2.635~5.548)、6.582(4.235~7.634)、8.917(6.344~9.213)、3.165(2.251~5.337),P<0.05]。血清镁预测CKD患者发生AS的曲线下面积为0.784(95%CI=0.731~0.832,P<0.05)。结论低血清镁水平是CKD患者发生AS的影响因素,低血清镁水平可能导致CKD患者发生AS风险增加。

拉贝洛尔联合硫酸镁治疗妊娠期高血压对HMGB1、HCY及CysC水平的影响研究

目的:研究拉贝洛尔联合硫酸镁治疗妊娠期高血压对血清高迁移率族蛋白B1(HMGB1)、同型半胱氨酸(HCY)及胱抑素C(CysC)水平对临床治疗的影响。方法:回顾性分析选取2020年8月—2021年10月南阳医学高等专科学校第一附属医院产科二病区收治的137例妊娠期高血压患者为研究对象,分析患者的临床资料,按照是否接受拉贝洛尔治疗分为联合组(n=68)和单一组(n=69)。联合组接受拉贝洛尔联合硫酸镁治疗,单一组给予硫酸镁治疗。对比两组患者治疗后的HMGB1、HCY和CysC水平改善程度、收缩压、舒张压以及分娩后情况。结果:治疗后,联合组患者HMGB1、HCY和CysC水平改善速度明显快于单一组,差异有统计学意义(P<0.05)。治疗后,联合组患者舒张压和收缩压均明显低于单一组,差异有统计学意义(t=16.890、20.684,P<0.05);联合组患者不良分娩情况出现率为4.41%,低于单一组的18.86%,差异有统计学意义(χ^(2)=5.918,P<0.05)。结论:对妊娠期高血压患者采用拉贝洛尔联和硫酸镁治疗干预,可以有效改善其血HMGB1、HCY和CysC水平,改善血压状况,避免分娩后出现较多分娩不良事件,该联合疗法值得临床采用并进行研究。

15,28日龄仔鹅血清与血浆生化指标的比较分析

为了比较仔鹅血清与血浆生化指标差异,试验选取健康的15,28日龄三花鹅公鹅各5只(不同日龄段鹅体重相近),每只鹅采集两份静脉血,每份2.0 mL,一份置于普通试管中用于制备血清,另一份置于肝素钠抗凝管中用于制备血浆,检测并比较分析不同日龄仔鹅血清和血浆体积及生化指标差异,包括电解质指标[钠(Na)、钾(K)、总钙(Ca)、无机磷(IP)、镁(Mg)、氯(Cl)]、肝脏功能指标[谷氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、AST/ALT、总胆红素(TBIL)、总蛋白(TP)、白蛋白(ALB)、球蛋白(GLO)、白球比(A/G)]、肾脏功能指标[尿酸(UA)、尿素氮(BUN)、肌酐(Cr)]、血脂成分[总胆固醇(TCHO)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、三酰甘油(TG)]。结果表明:15,28日龄仔鹅血清和血浆体积,Na、K、Ca、IP、Mg、Cl、TBIL、TP、ALB、GLO、UA、BUN、Cr、TCHO、HDL、LDL、TG浓度,AST、ALT活性及AST/ALT、A/G均差异不显著(P>0.05)。说明可用血浆代替血清进行1~28日龄仔鹅生化指标检测。

维持性血液透析患者血镁水平与腹主动脉钙化程度的相关性研究

目的探讨维持性血液透析(maintenance hemodialysis,MHD)患者血清镁(serum magnesium,Mg)水平与腹主动脉钙化(abdominal aortic calcification,AAC)程度的相关性。方法选取2021年1—3月暨南大学附属顺德医院收治的76例MHD患者作为本研究对象,根据患者的腹主动脉钙化评分(abdominal aortic calcification score,AACs)将所有患者分为Ⅰ组(0分≤AACs≤4分),Ⅱ组(5分≤AACs≤15分)和Ⅲ组(AACs≥16分);以1.065 mmol/L浓度的Mg作为临界值,将所有患者分为高Mg水平组和低Mg水平组。收集所有患者的一般临床资料、血清各项生化指标的水平值以及AACs具体评分情况。结果通过分析得出,MHD患者中存在AAC的患者共有36例,占比为47.37%;Ⅰ、Ⅱ、Ⅲ组患者年龄、空腹血糖、血清白蛋白(serum albumin,ALB)、Mg、血磷(serum phosphorus,Pi)、血清甲状旁腺激素(parathyroid hormone,PTH)水平值以及钙磷乘积比较,差异有统计学意义(P<0.05);Ⅰ组患者的Mg水平值明显较Ⅱ、Ⅲ组患者更高(P<0.05);Ⅱ组患者Mg水平值明显较Ⅲ组患者更高,差异有统计学意义(P<0.05);经Logistic多因素回归分析得出,Mg是AAC的保护因素,空腹血糖是AAC的影响因素;MHD患者中,高Mg水平组患者共有33例,其中AAC患者10例,占比为30.30%;低Mg水平组患者共有43例,AAC患者26例,占比为60.47%,差异有统计学意义(P<0.05);高Mg水平组患者Pi、PTH水平值、钙磷乘积均较低Mg水平组更低,而血钾(serum potassium,K)水平值相比低Mg水平组更高,差异有统计学意义(P<0.05);通过分析显示,血清Mg浓度与年龄、空腹血糖等均无相关性(P>0.05),与AAC,Pi、PTH指标,钙磷乘积均呈负相关(P<0.05),与K指标呈正相关(P<0.05)。结论MHD患者发生AAC的概率较高,患者血清中Mg浓度与AAC、Pi、K、钙磷乘积以及PTH水平均具有一定的相关性。

沙丁胺醇对妊娠期子宫肌瘤红色变性患者血液流变学和血清VEGF水平的影响

目的 探讨沙丁胺醇对妊娠期子宫肌瘤红色变性患者血液流变学、血清血管内皮生长因子(VEGF)水平的影响。方法 选择2020年1月至2022年4月西安安琪儿妇产医院妇产科收治的200例妊娠期子宫肌瘤红色变性患者纳入研究,按照随机数表法分为观察组和对照组各100例。在常规治疗基础上,对照组患者给予硫酸镁注射液治疗,直至宫缩消失24 h后停药,观察组患者在对照组治疗的基础上联合沙丁胺醇片治疗,直至患者腹痛消失4 d后停药。比较两组患者症状改善时间,治疗前、治疗7 d后的血液流变学指标(全血高切黏度、全血低切黏度)、血清VEGF水平的变化,同时比较两组患者的不良妊娠结局及治疗期间不良反应发生情况。结果 治疗后,观察组患者的体温正常时间、宫缩消失时间、腹痛消失时间分别为(3.35±0.67) d、(1.56±0.30) d、(4.21±0.69) d,明显短于对照组的(4.63±0.81) d、(3.17±0.64) d、(5.52±0.94) d,差异均有统计学意义(P<0.05);治疗后,观察组患者的全血高切黏度、全血低切黏度及血清VEGF水平分别为(2.98±0.31) m Pa·s、(5.49±0.76) m Pa·s、(113.23±19.56) ng/m L,明显低于对照组的(3.40±0.39) m Pa·s、(6.01±0.83) m Pa·s、(126.57±21.13) ng/mL,差异均有统计学意义(P<0.05);观察组患者的不良妊娠结局总发生率和不良反应总发生率分别为10.00%,4.00%,明显低于对照组的22.00%,12.00%,差异均有统计学意义(P<0.05)。结论 沙丁胺醇在妊娠期子宫肌瘤红色变性患者中的应用,可有效改善血液流变学、降低血清VEGF表达水平。

铝碳酸镁联合奥美拉唑对骨折患者术后应激性溃疡的作用价值

目的探讨铝碳酸镁联合奥美拉唑对骨折患者术后应激性溃疡(SU)的作用价值。方法选取2021年7月至2022年6月于抚州市第二人民医院骨科治疗的60例骨折术后SU患者作为研究对象,采用随机数字表法将其分为对照组(30例)及观察组(30例)。对照组患者采用奥美拉唑治疗,观察组患者于对照组基础上采用铝碳酸镁治疗。比较两组患者的治疗效果、血清胃泌素-17(G-17)、胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)、视觉模拟评分法(VAS)评分、世界卫生组织生活质量问卷调查表(WHOQOL-BREF)评分及不良反应发生情况。结果观察组患者的治疗总有效率(93.33%)高于对照组(73.33%),差异有统计学意义(P<0.05);治疗后,观察组患者的G-17、PGⅠ、PGⅡ水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者的VAS评分低于对照组,WHOQOL-BREF评分高于对照组,差异有统计学意义(P<0.05);两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论骨折术后SU患者采用铝碳酸镁与奥美拉唑联合治疗,有利于降低患者的G-17、PGⅠ及PGⅡ水平,改善胃肠道功能及生活质量,缓解疼痛程度,临床应用安全性高。